(Zero Hedge)—Two weeks after Rivian Automotive Inc. announced a disappointing production forecast and another round of job cuts, the company’s CEO revealed that the construction of a $5 billion factory in Georgia would be put on hold to reduce costs.
CEO RJ Scaringe unveiled a crossover EV called the R3. The new model will be priced lower than the R2 to increase affordability and boost sales.
Scaringe also surprised investors by announcing its new factory at the Georgia site east of Atlanta would be shelved.
“Rivian’s Georgia plant remains an extremely important part of its strategy to scale production of R2 and R3. The timing for resuming construction is expected to be later to focus its teams on the capital-efficient launch of R2 in Normal, Illinois,” the filing said.
The filing noted that the decision reduced capital expenditures for the automaker by $2.25 billion and “improved cash visibility.”
“Our Georgia site remains really important to us,” Scaringe said, adding, “It’s core to the scaling across all these vehicles, between R2, R3 and R3X. And we’re so appreciative of all the partnerships we’ve had there.”
No timetable was provided to investors about restarting work on the Georgia plant. Local governments have offered Rivian $1.5 billion in incentives to create thousands of jobs at the new plant.
Rivian’s shares jumped more than 13% on Thursday. In premarket trading in New York on Friday, shares are flat. Year-to-date performance has been awful, down 47%.
Short interest has surged in Rivian over the past year. Current data from Bloomberg shows 112.4 million shares short, or about 14.5% of the float is short.
Tom Narayan, an RBC Capital Markets analyst, warned in a note this week that Rivian’s financial implications of a lower-priced EV remain uncertain.
“Currently, R1 is losing money,” Narayan said, adding, “The critical question is how will Rivian be able to produce R2 profitably at the $45,000 price point?”
Last month, analyst Adam Jonas at Morgan Stanley penned a note titled “Can EV Slowdown Trigger Auto M&A Wave?”
“EV sentiment is extremely negative… and will eventually deteriorate further, in our view. Legacy OEMs must find a way to balance EV relevancy with capital discipline. Full OEM mergers are complex, politically sensitive and tough to execute. Could ‘merging’ EV projects be more reasonable?” Jonas said.
Consolidation is certainly a theme in the EV space this year.
What Would You Do If Pharmacies Couldn’t Provide You With Crucial Medications or Antibiotics?
The medication supply chain from China and India is more fragile than ever since Covid. The US is not equipped to handle our pharmaceutical needs. We’ve already seen shortages with antibiotics and other medications in recent months and pharmaceutical challenges are becoming more frequent today.
Our partners at Jase Medical offer a simple solution for Americans to be prepared in case things go south. Their “Jase Case” gives Americans emergency antibiotics they can store away while their “Jase Daily” offers a wide array of prescription drugs to treat the ailments most common to Americans.
They do this through a process that embraces medical freedom. Their secure online form allows board-certified physicians to prescribe the needed drugs. They are then delivered directly to the customer from their pharmacy network. The physicians are available to answer treatment related questions.
